UY39106A - Agonistas de gpr40 - Google Patents

Agonistas de gpr40

Info

Publication number
UY39106A
UY39106A UY0001039106A UY39106A UY39106A UY 39106 A UY39106 A UY 39106A UY 0001039106 A UY0001039106 A UY 0001039106A UY 39106 A UY39106 A UY 39106A UY 39106 A UY39106 A UY 39106A
Authority
UY
Uruguay
Prior art keywords
agonists
gpr40 agonists
disorder
gpr40
nash
Prior art date
Application number
UY0001039106A
Other languages
English (en)
Inventor
Shuwen He
Iyassu Sebhat
Simon Mathieu
Original Assignee
Kallyope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kallyope Inc filed Critical Kallyope Inc
Publication of UY39106A publication Critical patent/UY39106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta solicitud está dirigida, al menos en parte, a agonistas de GPR40 útiles para el tratamiento de afecciones o trastornos que involucran el eje intestino-cerebro. En algunas formas de realización, los agonistas de GPR40 son compuestos restringidos al tracto gastrointestinal. En algunas formas de realización, los agonistas de GPR40 son agonistas parciales o agonistas totales. En algunas formas de realización, la afección o trastorno es un trastorno metabólico, tal como diabetes, obesidad, esteatohepatitis no alcohólica (NASH) o un trastorno nutricional como el síndrome del intestino corto.
UY0001039106A 2020-02-28 2021-03-01 Agonistas de gpr40 UY39106A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062983438P 2020-02-28 2020-02-28
US202063076113P 2020-09-09 2020-09-09
US202063117074P 2020-11-23 2020-11-23
US202163147982P 2021-02-10 2021-02-10

Publications (1)

Publication Number Publication Date
UY39106A true UY39106A (es) 2021-09-30

Family

ID=77490353

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039106A UY39106A (es) 2020-02-28 2021-03-01 Agonistas de gpr40

Country Status (9)

Country Link
US (1) US20230151037A1 (es)
EP (1) EP4110760A1 (es)
JP (1) JP2023528713A (es)
CN (1) CN115867536A (es)
AU (1) AU2021225966A1 (es)
CA (1) CA3173732A1 (es)
TW (1) TW202140424A (es)
UY (1) UY39106A (es)
WO (1) WO2021174046A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291985A (en) 2019-10-07 2022-06-01 Kallyope Inc gpr119 agonists
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
CN116178281B (zh) * 2023-04-27 2023-07-21 中国药科大学 一种双功能免疫抑制剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011281134B2 (en) * 2010-07-23 2015-05-14 Connexios Life Sciences Pvt. Ltd. Agonists of GPR40
JP6095580B2 (ja) * 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
WO2015119899A1 (en) * 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
TW201613878A (en) * 2014-07-09 2016-04-16 Janssen Pharmaceutica Nv Pyrazine GPR40 agonists for the treatment of type II diabetes

Also Published As

Publication number Publication date
TW202140424A (zh) 2021-11-01
AU2021225966A1 (en) 2022-09-15
CN115867536A (zh) 2023-03-28
WO2021174046A1 (en) 2021-09-02
US20230151037A1 (en) 2023-05-18
JP2023528713A (ja) 2023-07-06
CA3173732A1 (en) 2021-09-02
EP4110760A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
UY39107A (es) Agonistas de gpr40
UY39106A (es) Agonistas de gpr40
CL2022000856A1 (es) Agonistas de gpr119
GT201700143A (es) Derivado de biarilo como agonista de gpr120
ATE555818T1 (de) Mehrschichtige cuffs für medizinprodukte
CL2008000017A1 (es) Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
ECSP088407A (es) Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia
DOP2019000068A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
HN2011001759A (es) Regimen de dosificacion para un agonista de los receptores de s1p
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
AR052059A1 (es) Plantas de cana azucarera con contenido incrementado de carbohidratos de almacenamiento
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
RU2013158109A (ru) Хирургический инструмент
ATE481059T1 (de) Einführvorrichtung für magenband
ECSP12011606A (es) Agonistas de gpr119
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..
PE20120909A1 (es) Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma
CL2022003208A1 (es) Activadores de la ampk
ECSP22094067A (es) Proceso para preparar un agonista dual glp-1/glucagón
UY38976A (es) Antagonistas de sstr5
BR112014008317A2 (pt) conjunto de prótese